Journal
NERVENARZT
Volume 71, Issue 8, Pages 597-610Publisher
SPRINGER
DOI: 10.1007/s001150050636
Keywords
multiple sclerosis; TNF alpha-antagonist; linomide; deoxyspergualine; sulfasalazine; IL-10; TGF-beta 2; IVlg; oral tolerance; extracorporeal photopheresis; cladribine; APL; altered peptide ligands
Categories
Ask authors/readers for more resources
Immunobiological findings together with advances in biotechnology, ameliorations in clinical trial design,and MRI developments have led to a variety of therapeutical approaches in multiple sclerosis (MS). However, in contrast to successfully introduced new treatments, a number of therapeutical failures exist as well: despite impressive data from animal models, convincing concepts, and promising phase MRI studies, some investigated drugs and strategies showed no positive effects in clinical trials, or trials had to be terminated because of unexpected side effects. This article provides an overview of clinical studies that have failed or been abandoned for other reasons. Tumor necrosis factor (TNF) alpha-antagonists which have led to negative effects in two studies (Lenercept, Infliximab) are discussed in detail. These results raise critical questions concerning the hypothetical pathogenesis of MS lesions a nd the value of MRI in the assessment of clinically relevant therapeutic drug effects. In addition to a description of the immunobiological background, studies on the immunosuppressive agents linomide, deoxyspergualin, sulfasalazine and cladribine, trials for the cytokines interleukin-10 and TGF-beta 2, the studies on remyelination by intravenous immunoglobulins (IVIg), oral tolerance, and extracorporeal photopheresis are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available